Summary & Overview
CPT 0590U: BIOTIA ID™ Urine NGS Assay for Uropathogen Detection
CPT code 0590U designates the BIOTIA ID™ Urine NGS Assay, a proprietary molecular diagnostic that sequences microbial DNA from urine to identify 44 potential uropathogens, reporting each as present or absent. As a PLA code, 0590U applies only to a single manufacturer's test and signals the growing use of targeted next-generation sequencing (NGS) panels in infectious disease diagnostics. Nationally, proprietary NGS-based urine testing is significant for guiding antimicrobial stewardship, improving pathogen detection in complicated urinary infections, and informing clinical decision-making where traditional culture may be limited.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, the clinical context for urine NGS testing, typical sites of service, and how PLA designation affects coding specificity. The publication outlines expected benchmarking topics such as coverage patterns, utilization drivers, and reimbursement considerations for proprietary laboratory tests, as well as policy updates affecting PLA codes and implications for laboratory and clinician billing workflows. The content is designed for a national audience of lab billing professionals, clinicians ordering molecular diagnostics, and payer policy analysts.
Billing Code Overview
CPT code 0590U is a Proprietary Laboratory Analyses (PLA) code that specifically identifies the BIOTIA ID™ Urine NGS Assay from Biotia Inc. The assay sequences microbial DNA directly from urine to detect 44 potential uropathogens and reports each organism as present or absent.
Service type: Molecular diagnostic, next-generation sequencing (NGS) microbial detection assay.
Typical site of service: Clinical laboratory testing on urine specimens; results used to inform outpatient or inpatient clinical care.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female presents to a urology clinic with recurrent symptoms of dysuria, urinary frequency, and urgency despite prior empiric antibiotic courses. Urine dipstick and standard culture were inconclusive or showed mixed flora. The clinician orders the BIOTIA ID™ Urine NGS Assay (0590U) to identify a broad panel of 44 potential uropathogens by sequencing microbial DNA directly from a clean-catch or catheterized urine sample. The clinical workflow: specimen collection in the outpatient clinic or hospital; secure packaging and shipment to the performing laboratory; laboratory receipt and processing using the proprietary NGS assay; generation of a report indicating each organism as present or absent; clinician review of results to guide targeted antimicrobial selection or further diagnostic evaluation. Typical sites of service include outpatient clinics, ambulatory surgical centers, emergency departments, and inpatient hospital settings where urine specimens are collected and sent to a reference laboratory.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when documentation supports substantially greater effort or complexity in specimen handling or reporting beyond the typical assay workflow. |